Seer (SEER) Liabilities and Shareholders Equity (2020 - 2026)
Seer (SEER) recorded quarterly Liabilities and Shareholders Equity of $272.1 million in Q1 2026, down 8.09% quarter-over-quarter from $296.1 million in Q4 2025, and down 21.63% on a YoY basis from $347.3 million in Q1 2025.
Seer (SEER) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Seer's Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $272.1 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 21.63% year-over-year to $272.1 million; the TTM figure through Mar 2026 stood at $1.2 billion (down 20.25% YoY), while the FY2025 annual figure was $296.1 million, down 19.23% from the prior year.
- Liabilities and Shareholders Equity was $272.1 million for Q1 2026 at Seer, down from $296.1 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $527.1 million in Q1 2022 to a low of $272.1 million in Q1 2026.
- Historically, Liabilities and Shareholders Equity has averaged $410.1 million across 5 years, with a median of $422.0 million in 2024.
- The sharpest annual moves came in 2022 and 2026: Liabilities and Shareholders Equity retreated 3.4% in 2022, then slipped 21.63% in 2026.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $487.9 million in 2022, then slipped by 10.59% to $436.3 million in 2023, then decreased by 15.97% to $366.6 million in 2024, then decreased by 19.23% to $296.1 million in 2025, then declined by 8.09% to $272.1 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $272.1 million (Q1 2026), $296.1 million (Q4 2025), and $308.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 37.37 Mn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 811.27 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 14.93 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 1.73 Bn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 33.89 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | 23.64 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 12.81 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 26.48 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 640.56 Mn |
| 10 | Seer | 99.67 Mn | 99.67 Mn | 982,000.00 | 272.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 272.13 Mn |
| Dec 31, 2025 | 296.08 Mn |
| Sep 30, 2025 | 308.61 Mn |
| Jun 30, 2025 | 322.49 Mn |
| Mar 31, 2025 | 347.26 Mn |
| Dec 31, 2024 | 366.60 Mn |
| Sep 30, 2024 | 383.42 Mn |
| Jun 30, 2024 | 406.61 Mn |
| Mar 31, 2024 | 421.96 Mn |
| Dec 31, 2023 | 436.27 Mn |
| Sep 30, 2023 | 444.85 Mn |
| Jun 30, 2023 | 461.20 Mn |
| Mar 31, 2023 | 472.79 Mn |
| Dec 31, 2022 | 487.93 Mn |
| Sep 30, 2022 | 500.21 Mn |
| Jun 30, 2022 | 516.30 Mn |
| Mar 31, 2022 | 527.09 Mn |
| Dec 31, 2021 | 539.14 Mn |
| Sep 30, 2021 | 527.84 Mn |
| Jun 30, 2021 | 537.05 Mn |